NCT02388100已完成不适用
The Glycemia Reduction Approaches in Diabetes: a Comparative Effectiveness Study (GRADE Study) Capillary Blood Collection: a Pilot Study
GRADE Study Group5 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2015年3月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 70
- 试验地点
- 5
- 主要终点
- HbA1c obtained from venous versus capillary measurements at one point in time for each participant.
研究概览
简要总结
This pilot study is planned to validate the comparability of HbA1c results obtained from whole blood collection via venous phlebotomy versus a capillary collection of whole blood. The participant will self-collect capillary blood into HbA1c prep vials containing a buffer; these prep vials will be sent to the CBL at ambient temperature via US Postal System (USPS) mail. The feasibility of self-collection of these capillary samples by GRADE participants will also be evaluated.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Current GRADE participant with a scheduled follow-up visit
排除标准
- •GRADE participants attending first quarterly (Month 3) visit or an annual visit
结局指标
主要结局
HbA1c obtained from venous versus capillary measurements at one point in time for each participant.
时间窗: Cross sectional
次要结局
未报告次要终点
研究者
研究点 (5)
Loading locations...
相似试验
已完成
3 期
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 DiabetesComparative Effectiveness of Glycemia-lowering MedicationsType 2 DiabetesNCT01794143GRADE Study Group7,850
已完成
1 期
A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 DiabeticsDiabetes Mellitus, Type 2NCT01147861GlaxoSmithKline39
进行中（未招募）
不适用
Pilot study to assess the difference in glycemic profiles between vildagliptin and glimepiride using CGM deviceEUCTR2010-021236-34-DEovartis Pharma Services AG
已完成
不适用
HbA1c Variation StudyDiabetes MellitusNCT05189938Abbott Diabetes Care488
已完成
2 期
Safety and Tolerability Study of MBX-2044 in Patients With Type 2 DiabetesType 2 Diabetes MellitusNCT00422487CymaBay Therapeutics, Inc.60